EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Clinical and Biochemical Factors Associated With Infliximab Pharmacokinetics in Adult Patients With Inflammatory Bowel Disease

Ilse A Pool, Ilse Volkerink, Mirthe Stavast, Jos G W Kosterink, Gerard Dijkstra, Paola Mian iD, Arno R Bourgonje iD

The Journal of Clinical Pharmacology · 2026-01 · 66 (1)

DOI: 10.1002/jcph.70111 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 25.09.2025. Verfasst von Ilse A Pool und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Gastrointestinal Agents, Inflammatory Bowel Diseases, Infliximab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Rubicon fellowship, EU Horizon Health, Innovation Health Initiative Joint Undertaking.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Many patients with inflammatory bowel disease (IBD) do not adequately respond to infliximab, potentially due to individual differences in pharmacokinetics (PK). This study aimed to identify clinical and biochemical variables associated with infliximab PK. Adult IBD patients treated with infliximab and with registered infliximab trough levels between March 1, 2021 and November 22, 2023, were included. Univariable and multivariable linear mixed‐effects models were used to evaluate associations between clinical and biochemical covariates and infliximab trough levels. A systematic literature review was conducted to contextualize findings. The study included 259 patients (CD: n = 202; UC: n = 47; IBD‐unclassified: n = 10) with 560 infliximab trough levels available for analysis. Higher hemoglobin was associated with lower infliximab levels (IBD: β = 0.668, p = 0.036; UC: β = 1.639, p = 0.018), as were albumin (IBD: β = 0.214, p = 0.002; CD: β = 0.345, p < 0.001) and AST (CD: β = 0.040, p = 0.019). Inverse associations were also found for ALT (UC: β = −0.100, p = 0.016), ALP (CD: β = −0.029, p = 0.021; UC: β = −0.018, p = 0.037) and GGT (IBD: β = −0.015, p = 0.028; UC: β = −0.034, p < 0.001). Endoscopic inflammation was positively associated with infliximab levels in CD (β = 3.402, p = 0.035). Systemic steroid use was associated with lower infliximab levels in UC (β = −4.263, p = 0.013). In conclusion, this study identified several clinical and biochemical variables, including albumin, hemoglobin and GGT across all patients, albumin, AST and ALP in CD, and hemoglobin, ALT, ALP and GGT in UC, that were associated with infliximab trough levels. Given the correlative nature of this study, these results should be interpreted cautiously. These findings merit validation and could inform model‐informed precision dosing strategies in IBD clinical care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal AgentsInflammatory Bowel DiseasesInfliximabAdultHumansMale

Stichwörter der Autor:innen

Inflammatory bowel diseaseinfliximabpharmacokineticstherapeutic drug monitoring

Substanzen

Gastrointestinal AgentsInfliximab

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of PharmacoTherapy, Epidemiology and Economy, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.
  • Department of Pediatrics, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Medicine, The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

ORCID-Profile: Paola Mian, Arno R Bourgonje

Förderung

  • Rubicon fellowship
  • EU Horizon Health
  • Innovation Health Initiative Joint Undertaking
  • EU Horizon Europe Program
  • European Union or the European Research Council

Zitieren

APA

Pool, I. A., Volkerink, I., Stavast, M., Kosterink, J. G. W., Dijkstra, G., Mian, P., & Bourgonje, A. R. (2026). Clinical and Biochemical Factors Associated With Infliximab Pharmacokinetics in Adult Patients With Inflammatory Bowel Disease. The Journal of Clinical Pharmacology, 66(1). https://doi.org/10.1002/jcph.70111

Vancouver

Pool IA, Volkerink I, Stavast M, Kosterink JGW, Dijkstra G, Mian P, et al. Clinical and Biochemical Factors Associated With Infliximab Pharmacokinetics in Adult Patients With Inflammatory Bowel Disease. The Journal of Clinical Pharmacology. 2026;66(1). doi:10.1002/jcph.70111

BibTeX
@article{Pool2026,
  author = {Pool, Ilse A and Volkerink, Ilse and Stavast, Mirthe and Kosterink, Jos G W and Dijkstra, Gerard and Mian, Paola and Bourgonje, Arno R},
  title = {Clinical and Biochemical Factors Associated With Infliximab Pharmacokinetics in Adult Patients With Inflammatory Bowel Disease},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  volume = {66},
  number = {1},
  doi = {10.1002/jcph.70111}
}
Kostenlos starten →